Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

Revenue projections:

Revenue projections for REGN
Revenue projections for REGN

REGN is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 4.126000
forwardPE 14.349785
debtToEquity 9.511000
earningsGrowth -0.026000
revenueGrowth 0.025000
grossMargins 0.445660
operatingMargins 0.231340
trailingEps 41.510000
forwardEps 52.993130

The current ratio for REGN is 4.126, indicating that the company can service its short-term debt using available cash and assets. This suggests REGN has strong liquidity, with more than enough resources to meet its immediate financial commitments.
REGN's Forward PE being in a good range suggests that its stock price is aligned well with earnings. The stock is not considered overpriced, offering room for future growth, which makes it an appealing investment opportunity with the potential for value appreciation.
REGN's low earnings and revenue growth point to a likely decrease in profits. This suggests that the company is facing financial difficulties and may struggle to maintain its current level of profitability.
REGN's positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
REGN's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that REGN is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for REGN
Price projections for REGN

REGN's price has consistently hovered around the lower limit of price projections. This pattern suggests that the stock may be underperforming relative to expectations, which could lead to concerns among investors.

Insider Transactions:

Insider Transactions for REGN
Insider Transactions for REGN


8 separate sales of REGN shares were executed, with the market price hovering at 748.8037567138672.The period under consideration saw no sell transactions.The trend of more buys than sells at Regeneron Pharmaceuticals, Inc.'s current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.

Recommendation changes over time:

Recommendations trend for REGN
Recommendations trend for REGN


Recent analysis shows a strong buy bias for Regeneron Pharmaceuticals, Inc., encouraging investors to view it as a solid investment option. The positive sentiment surrounding Regeneron Pharmaceuticals, Inc. suggests it could be an attractive place to allocate funds, motivating potential investors to consider the stock as a valuable part of their portfolio.